Navigation Links
Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference
Date:2/13/2008

PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Dr. Leslie J. Browne, President and Chief Executive Officer, will deliver a corporate presentation at the Roth 20th Annual OC Growth Stock Conference. The conference will be held February 18-21, 2008, at The Ritz Carlton Laguna Niguel in Dana Point, CA.

Dr. Browne's presentation will take place at 10:30 a.m. local time on Thursday, February 21st. The presentation will include an overview of the company's drug development pipeline, including an update on its internal clinical programs, PS433540 (DARA), which is progressing in Phase 2, and PS178990 (SARM), which is currently in Phase 1. A live webcast and 90-day archive of the presentation can be accessed at http://www.pharmacopeia.com.

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

(609) 452-3643

ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
2. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
3. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
4. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
5. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
6. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
7. Pharmacopeia Announces Senior Additions to Management Team
8. Pet DRx to Present at Roth 20th Annual OC Growth Stock Conference
9. AtriCure to Present at Roth Capital Partners 20th Annual OC Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
11. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC ... of medical professionals throughout the country. The Guard was specifically designed to handle ... procedures, employee training, regulatory updates, and compliance coaching. , In addition to meeting ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Dr. Jessica Barron, ... practice is now accepting new dental patients and families in the North Metro Denver ... care services from cleanings to cosmetic dentistry, and all in the most relaxing environment. ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the ... ended December 31, 2015 on Monday, February 29, 2016 after the market closes. , ... the release at 4:30 PM ET. Investors interested in participating by phone are invited ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
(Date:2/11/2016)... CITY, Calif. , Feb. 11, 2016  AcelRx ... a podium presentation will be made at the 38th ... and Wound Care Symposium, which is being held ... This international conference covers the latest advancements in wound ... by the American Burn Association, Australian-New Zealand Burns Association, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology: